The emergence of cancer immunotherapy has already shown some remarkable results for the treatment of solid tumors. As good as this is, patients seem to lack the ability to respond to immune checkpoint inhibitors, thus demonstrating a primary resistance to immunotherapy. By reducing tumor hypoxia (low oxygen) within solid tumors. hyperbaric oxygen therapy (HBOT) can help reinvigorate anti-cancer immunity. In this study, HBOT was able to stimulate a suppressed immune system and help PD-1 Ab trigger robust cytotoxic T lymphocytes and long-lasting immunological memory to inhibit tumor relapses. Emerging research suggests that T cell-directed checkpoint antibodies such as anti-programmed cell death protein-1 (PD-1) or programmed death-ligand-1 (PD-L1) can impact innate immunity by both direct and indirect pathways, which may ultimately shape clinical efficacy. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.. Hyperbaric Oxygen Boosts PD-1 Antibody Delivery -- "The results illustrate that HBO bolsters antitumor efficacy of PD-1 Ab, and the HBO-PD-1 Ab combination is a promising stroma-rich solid tumors' treatment in the clinic" <view study> Read Less

Hyperbaric protocols can vary in dosages, based on both pressure and time. Higher-pressure protocols are typically used in hospitals and wound care centers for radiation induced damage. These pressure protocols range from 2.0 to 2.4 ATA. This study shows that 2.0 ATA (120 minutes) was equally as effective as 2.4 ATA (90 minutes) for treating radiation-induced cystitis <view study> Read Less

Telomere length serves as a biological clock to determine our lifespan.  Every year, our telomeres (the ends of our DNA) get shorter until they finally shorten to a length that leads to our mortality. Over the past few decades, researchers and drug companies have focused (and invested substantial capital) on this  key biological determinant (telomere length) in the hopes of being able to stop and reverse the aging process. Since many age-related diseases (like cancer, cardiovascular diseases, diabetes and Alzheimer’s) are also linked to shortened telmeres, it is easy to see why so many drug and nutritional companies have been working hard on finding a cure to stop and reverse the shortening of telomeres. Hyperbaric oxygen therapy has already been demonstrated in clinical studies to help the aging population by reducing the signs of aging and age-related diseases. In 2006, a landmark study showed an 800% increase in stem cell mobilization from a course of hyperbaric oxygen therapy. This gave us a much better understanding of the physiological benefits of this procedure in relation to the aging process. Today we have even more information as a second landmark study has been published on the effects of hyperbaric  therapy in regards to telomere length. In this study, a 3 month course of hyperbaric therapy produced a profound increase in telomere length by 20% - 38%. (This is higher than any other intervention currently available). The hyperbaric protocol used to produce these benefits included 60 hyperbaric sessions (each at 90 minute sessions at 2.0 ATA  with 3 air breaks). This exciting new study will surely lead to many more telomere-based studies in the field of hyperbaric oxygen therapy and further help to advance our knowledge of this therapy.  <View Full Study in the JOURNAL OF AGING> Due to the significance of this study, it has quickly been picked up by many news associations like the following:

• <view in the Independent>
• <view in yahoo news>
• <view in the telegraph>
• <view in aljazeera>
• <view in Science alert>
• <view in Neuroscience news>

Read Less

“In this case-series, 67 patients who underwent HBOT for late radiation tissue injury after breast cancer reported significant improvement in pain, fibrosis, edema, and shoulder movement. The improvement persisted up to 12 months after HBOT” <view study> Read Less

The combination of metabolically supported chemotherapy, together with a ketogenic diet, hyperthermia and HBOT, appears to be promising in the treatment of advanced gastric cancer. <view study> Read Less